Open AccessThis article is
- freely available
Department of Drug Sciences, “G. d'Annunzio” University, School of Pharmacy, Via dei Vestini 31, 66100 Chieti, Italy
* Author to whom correspondence should be addressed.
Received: 4 December 2007; in revised form: 11 January 2008 / Accepted: 11 January 2008 / Published: 16 January 2008
(This article belongs to the Special Issue Prodrugs
Abstract: Parkinson`s disease (PD) is a progressive, neurodegenerative disorder whichinvolves the loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is essentially symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice in more advanced stages of the disease. Substitutiontherapy with LD is, however, associated with a number of acute problems. The peripheralconversion of LD by amino acid decarboxylase (AADC) to DA is responsible for thetypical gastrointestinal (nausea, emesis) and cardiovascular (arrhythmia, hypotension) sideeffects. To minimize the conversion to DA outside the central nervous system (CNS) LD isusually given in combination with peripheral inhibitors of AADC (carbidopa andbenserazide). In spite of that, other central nervous side effects such as dyskinesia, on-offphenomenon and end-of-dose deterioration still remain. The main factors responsible forthe poor bioavailability and the wide range of inter- and intra-patient variations of plasmalevels are the drug’s physical-chemical properties: low water and lipid solubility, resultingin unfavourable partition, and the high susceptibility to chemical and enzymaticdegradation. In order to improve the bioavailability, the prodrug approach appeared to bethe most promising and some LD prodrugs have been prepared in an effort to solve theseproblems. We report here a review of progress in antiparkinson prodrugs, focusing onchemical structures mainly related to LD, DA and dopaminergic agonists.
Keywords: L-dopa; Dopamine; Prodrugs; antiparkinson
Citations to this Article
Cite This Article
MDPI and ACS Style
Di Stefano, A.; Sozio, P.; Cerasa, L.S. Antiparkinson Prodrugs. Molecules 2008, 13, 46-68.
Di Stefano A, Sozio P, Cerasa LS. Antiparkinson Prodrugs. Molecules. 2008; 13(1):46-68.
Di Stefano, Antonio; Sozio, Piera; Cerasa, Laura S. 2008. "Antiparkinson Prodrugs." Molecules 13, no. 1: 46-68.